Sovateltide (development names IRL-1620 and PMZ-1620,[1] sold in India under the brand name Tyvalzi)[2] is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz.[2] Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis).[3][4] Sovateltide also protects neural mitochondria and enhances their biogenesis.[5]

Sovateltide
Clinical data
Trade namesTyvalzi
Other namesIRL-1620; PMZ-1620
Legal status
Legal status
  • Rx in India
Identifiers
  • Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC86H117N17O27
Molar mass1820.974 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
  • InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
  • Key:DXPHNGAMYPPTBJ-TZMIJSMNSA-N

References

edit
  1. ^ Gulati, Anil; Agrawal, Nilesh; Vibha, Deepti; Misra, U. K.; Paul, Birinder; Jain, Dinesh; Pandian, Jeyaraj; Borgohain, Rupam (January 2021). "Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke". CNS Drugs. 35 (1): 85–104. doi:10.1007/s40263-020-00783-9. ISSN 1179-1934. PMC 7872992. PMID 33428177.
  2. ^ a b Keam, Susan J. (September 2023). "Sovateltide: First Approval". Drugs. 83 (13): 1239–1244. doi:10.1007/s40265-023-01922-4. ISSN 1179-1950. PMID 37486545. S2CID 260114948.
  3. ^ Ranjan, Amaresh K.; Gulati, Anil (2022-03-15). "Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders". International Journal of Molecular Sciences. 23 (6): 3146. doi:10.3390/ijms23063146. ISSN 1422-0067. PMC 8955091. PMID 35328566.
  4. ^ Ranjan, Amaresh K.; Briyal, Seema; Khandekar, Divya; Gulati, Anil (September 2020). "Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke". Canadian Journal of Physiology and Pharmacology. 98 (9): 659–666. doi:10.1139/cjpp-2020-0164. ISSN 0008-4212. PMID 32574518.
  5. ^ Ranjan, Amaresh K.; Briyal, Seema; Gulati, Anil (2020-07-29). "Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke". Scientific Reports. 10 (1): 12737. Bibcode:2020NatSR..1012737R. doi:10.1038/s41598-020-69673-w. ISSN 2045-2322. PMC 7391684. PMID 32728189.